Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Tofacitinib Clears FDA Without Limited Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

With FDA’s early approval of tofacitinib for rheumatoid arthritis – the first JAK inhibitor and, unlike the popular TNF inhibitors, an oral agent – the agency appears to have sided with Pfizer on many issues left up in the air after an advisory committee review.

You may also be interested in...



Could FDA Force Pfizer To Push Shingles Vaccination With Xeljanz Psoriatic Arthritis Approval?

Arthritis Advisory Committee members say the company should bear some of the responsibility for managing the risk of shingles with the JAK inhibitor.

Pfizer's Xeljanz: The Slow Road To Blockbuster Status

The oral pill, perhaps best known to investors for failing to live up to initial expectations in rheumatoid arthritis, has found its groove – and new opportunities in psoriatic arthritis and ulcerative colitis are on the horizon.

Beyond Xeljanz: An Inflammation & Immunology Portfolio Blooms At Pfizer

Xeljanz’s launch in rheumatoid arthritis has gotten off to a slower than expected start, highlighting the challenges for new drugs in competitive inflammatory diseases. But Pfizer is digging in its heels and hoping that pipeline drugs, including next-generation JAKs, will stand out by addressing unmet medical need in indications like lupus, type1 diabetes and inflammatory bowel disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel